Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand?
Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994; 83: 2392-8.
Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia
Shepp DH, Dandliker PS, de Miranda P et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985; 103: 368-73.
Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function
Sommadossi JP, Bevan R, Ling T et al. Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 1988; S507-14.
Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation
Gondo H, Minematsu T, Harada M et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86: 130-7.
Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation
Kanda Y, Mineishi S, Saito T et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: A prospective evaluation. Transplantation 2002; 73: 568-72.
Ganciclovir in solid organ transplant recipients: Is there a role for clinical pharmacokinetic monitoring?
Scott JC, Partovi N, Ensom MHH. Ganciclovir in solid organ transplant recipients: Is there a role for clinical pharmacokinetic monitoring? Ther Drug Monit 2004; 26: 68-77.
Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised host
Erice A, Jordan MC, Chace BA et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised host. JAMA 1987; 257: 3082-7.
Pre-emptive therapy against cytomegalovirus (CMV) diseases guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: A single-center experience in Japan
Kanda Y, Mineishi S, Saito T et al. Pre-emptive therapy against cytomegalovirus (CMV) diseases guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: A single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-44.